Welcome to our dedicated page for Enzon Pharma SEC filings (Ticker: ENZN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Enzon Pharmaceuticals, Inc. (ENZN) files a range of documents with the U.S. Securities and Exchange Commission that are central to understanding its role as a public company acquisition vehicle and its proposed merger with Viskase Companies, Inc. On this page, you can review Enzon’s Form 8-K current reports, which detail material events such as the execution of the Agreement and Plan of Merger, subsequent amendments to that agreement, and changes to its Section 382 Rights Agreement.
Merger-related 8-K filings describe the structure of the all-stock transaction in which Viskase will merge with and into a wholly owned Enzon subsidiary, the exchange ratios between Viskase common stock, Enzon common stock, and Enzon’s Series C Non-Convertible Redeemable Preferred Stock, and the anticipated post-merger ownership split, including the expectation that current Viskase stockholders will own 55% of the combined company following the amended merger terms. These filings also outline requirements such as a 1-for-100 reverse stock split of Enzon common stock and the role of Icahn Enterprises Holdings L.P. and its affiliates under a support agreement.
Other key filings relate to Enzon’s Section 382 Rights Agreement. Through multiple amendments reported on Form 8-K, Enzon has adjusted the Final Expiration Date of the rights issued under this agreement. The company notes that these amendments are intended to revise the expiration date while leaving the rest of the agreement unchanged, and that management believes the revised dates are in the best interests of stockholders.
Enzon has also stated that it intends to file a registration statement on Form S-4 in connection with the Viskase merger. That filing is expected to contain a consent solicitation statement and prospectus and to include financial information about the combined company. On this page, AI-powered tools can help summarize lengthy filings, highlight key transaction terms, and make it easier to understand complex documents such as merger agreements, rights agreements, and related exhibits.
Enzon Pharmaceuticals, Inc. filed Amendment No. 1 to its Form S-4 registration statement as an exhibits-only update connected to its proposed merger with Viskase Companies, Inc. and EPSC Acquisition Corp.
The amendment mainly lists and files key agreements, including the June 20, 2025 Agreement and Plan of Merger and the October 24, 2025 first amendment to that merger agreement, multiple amendments to Viskase’s credit agreement through January 23, 2026, and a Support Agreement with Icahn Enterprises Holdings L.P. and affiliates. It also includes numerous consents from auditors, legal counsel, proposed directors, and financial advisors, as well as transaction documents like letters of transmittal and notices of guaranteed delivery. The filing does not change the substantive terms previously disclosed, but formally adds and organizes the transaction-related exhibits.
Enzon Pharmaceuticals, Inc. has amended its Section 382 Rights Agreement again, entering into a Seventh Amendment on January 30, 2026. This amendment changes the Final Expiration Date of the rights from the close of business on January 31, 2026 to noon New York City time on March 2, 2026.
The company states that management believes setting the new March 2, 2026 expiration is in the best interests of the company and its stockholders. Aside from this new expiration timing, all other terms of the Rights Agreement and prior amendments remain unchanged.
Enzon Pharmaceuticals, Inc. is registering up to 7,935,878 shares of common stock in connection with its proposed merger with Viskase Companies, Inc. and a related exchange offer for its Series C preferred stock. The S-4 also serves as a consent solicitation for Enzon stockholders.
Under the Merger Agreement, Enzon’s subsidiary will merge into Viskase, which will become a wholly owned subsidiary and then convert into a Delaware LLC, with the combined company renamed Viskase Holdings, Inc. and quoted on the OTCQB. Enzon will first implement a 1-for-100 reverse stock split, subject to stockholder approval.
Enzon also plans a Series C Exchange Offer, letting holders swap each Series C preferred share for common stock based on a volume-weighted average price of $0.08 per share (or $7.83 after the reverse split). Assuming full exchanges, former Enzon common holders are expected to own about 5% of the combined company, former Series C holders about 40%, and Viskase stockholders about 55%.
Enzon Pharmaceuticals, Inc. disclosed that it entered into a Sixth Amendment to its Section 382 Rights Agreement with Continental Stock Transfer & Trust Company. This amendment changes only the Final Expiration Date of the rights issued under the agreement, moving it from the close of business on December 31, 2025 to the close of business on January 31, 2026.
The company notes that, apart from this new expiration date, all other terms of the Rights Agreement remain unchanged. Management states that adopting a Final Expiration Date of January 31, 2026 is believed to be in the best interests of the company and its stockholders. The amendment is filed as an exhibit and incorporated by reference along with the prior amendments to the Rights Agreement.
Enzon Pharmaceuticals (ENZN) filed its Q3 2025 10‑Q, highlighting progress on its planned all‑stock merger with Viskase and a cash‑heavy balance sheet with minimal operations. Cash and cash equivalents were $43.3 million at September 30, 2025, down from $46.9 million at year‑end, reflecting transaction costs and preferred dividends.
Operations remain limited: Enzon reported no revenue in Q3, interest and dividend income of $496,000 (down 24%), and transaction expenses of $1.1 million tied to the Viskase deal. Net loss was $824,000 for the quarter, or a net loss available to common shareholders of $1.4 million, with basic and diluted loss per share of $0.02. Stockholders’ equity shifted to a deficit of $923,000, while Series C preferred stock liquidation value rose to $44.1 million due to 5% accretion.
The merger agreement with Viskase, amended October 24, 2025, anticipates post‑closing ownership of approximately 45% for current Enzon holders and 55% for Viskase holders. Icahn Enterprises Holdings L.P. agreed to provide written consents and to exchange all Series C preferred shares into common stock based on full liquidation preference and the 20‑Day VWAP before closing. Enzon moved to the OTCQB Market on August 12, 2025 after falling below a $0.10 bid price threshold.
Enzon Pharmaceuticals (ENZN) filed Amendment No. 17 to Schedule 13D reflecting updated terms to its merger with Viskase. The amendment states that current Viskase stockholders will own 55% of the combined company after the merger, the exchange ratio for Enzon’s Series C Preferred will be based on the 20‑Day VWAP, and Enzon will conduct a 1‑for‑100 reverse stock split before the merger’s effective time. The minimum cash required at closing is reduced, and the outside date to terminate the agreement is extended to March 31, 2026.
Icahn Enterprises Holdings agreed to deliver written consents approving the merger and a charter amendment, and to exchange all of its Series C Preferred into common shares based on full liquidation preference and the 20‑Day VWAP. The filing reports 36,056,636 shares beneficially owned with 48.6% of the class, with shared voting and dispositive power.
Enzon Pharmaceuticals amended its merger agreement with Viskase Companies and the related support agreement with Icahn Enterprises Holdings (IEH). The updates reflect recent developments at Viskase and expected near‑term operations. A Special Committee of independent directors at both companies recommended the amendments, and each board approved them.
Under the amended IEH support agreement, IEH will deliver written consents for all Enzon common shares it holds to approve the merger and a charter amendment. IEH will also exchange all Series C Preferred Stock into Enzon common stock before closing, based on the full liquidation preference and the 20‑Day VWAP.
Enzon plans to file a Form S‑4 including a consent solicitation statement to seek shareholder approval for the amended merger terms, a name change to Viskase Holdings, Inc., and a Reverse Stock Split. The combined company’s board is anticipated to include Jordan Bleznick, Randolph C. Read, and additional directors designated by Viskase. Enzon believes its net operating losses and other tax benefits will be maintained and available to the combined company following the merger.
Enzon Pharmaceuticals, Inc. has amended its Section 382 Rights Agreement again to adjust the length of its shareholder rights plan. On September 30, 2025, the company entered into a Fifth Amendment that changes the Final Expiration Date of the rights from the close of business on September 30, 2025 to the close of business on December 31, 2025. This plan is designed under Section 382 of the tax code, which typically relates to preserving tax attributes such as net operating losses by discouraging certain changes in ownership.
The company notes that, aside from extending the Final Expiration Date, the terms of the Rights Agreement remain unchanged. Management states that it believes setting a Final Expiration Date of December 31, 2025 is in the best interests of the company and its stockholders. Prior amendments had repeatedly adjusted the expiration date over the last several years, and all versions of the agreement and amendments are incorporated by reference as exhibits.